Market Cap
$1.2B
AVNS
AVANOS MEDICAL, INC.
—
Market cap$1.2B
High Impact Filing (7/10)27 New Institutional Positions23 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on AVNS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$720.2M
Inst. Activity
27 buys / 23 sells
SEC Reports
7
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 3, 2026 earnings_calendar
Jul 27, 2026 SEC AVNS Q2 2026 Earnings Scheduled — 2026-08-03
The New York Stock Exchange filed a Form 25-NSE to delist Avanos Medical, Inc. (AVNS) following the completion of its go
25-NSE — Impact 5/10
Jul 27, 2026 Insider
Galovan Scott Michael was granted 96,121 shares
SVP, Chief Financial Officer
Jul 27, 2026 Insider
Delgado Sigfrido was granted 54,886 shares
SVP, Operations
Jul 27, 2026 Insider
Jul 2, 2026 SEC Galovan Scott Michael disposed of 96,121 shares
SVP, Chief Financial Officer @ $25.00 ($2.4M)
Avanos Medical received all required regulatory approvals for its pending acquisition by American Industrial Partners (A
8-K, DEFA14A — Impact 7/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
1,524,553 shares ($37.9M)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — DOUBLED
1,099,770 shares ($27.4M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 7, 2024 | JMP Securities | REITERATE | Market Perform | 53% |
| Jul 25, 2023 | Keybanc | DOWNGRADE | Sector Weight | 52% |
| Jun 21, 2023 | Stifel | REITERATE | Hold | 54% |
| May 22, 2023 | CL King | INITIATE | Buy | 50% |
| May 4, 2023 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Feb 22, 2023 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Jan 6, 2023 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Nov 3, 2022 | Keybanc | MAINTAIN | Overweight | 52% |
| Oct 11, 2022 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Aug 10, 2022 | Keybanc | MAINTAIN | Overweight | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Aug 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 6.0/10.
NEUTRAL25-NSE5/10
The New York Stock Exchange filed a Form 25-NSE to delist Avanos Medical, Inc. (AVNS) following the
Jul 27, 2026
BULLISH8-K, DEFA14A7/10
Avanos Medical received all required regulatory approvals for its pending acquisition by American In
Jul 2, 2026
BULLISHDEFM14A8/10
Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP) fo
Jun 10, 2026
NEUTRALDEFA14A5/10
Avanos Medical filed additional definitive proxy soliciting materials (DEFA14A) related to its pendi
May 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 3, 2026
earnings_calendar
AVNS Q2 2026 Earnings Scheduled — 2026-08-03
Jul 27, 2026
listing_status
Delisted: AVNS — removed from the N symbol directory
Avanos Medical, Inc. Common Stock
Jun 15, 2026
short_interest_report
Short Interest: AVNS up 47% to 1.7M shares
Settlement 2026-06-15 | Days to cover: 1.20 | ≈3.66% of shares outstanding (est.)
May 27, 2026
Enforcement
HSR Early Termination: AIPCF VIII Indirect Investor AIV LP; Avanos Medical, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving AIPCF VIII Indirect Investor AIV LP; Avanos Medical, Inc..
May 7, 2026
short_volume
Short Volume: AVNS — 67.3% short (0.6M / 0.9M)
Short: 614,991 | Exempt: 22 | TRF Vol: 914,396 | Short Ratio: 67.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next Q | $0.33 | $0.33–$0.33 | 50.0% | +0.0% | 1↑ 0↓ | $0.2B | 1 |
| Current FY | $1.00 | $1.00–$1.00 | 6.4% | +0.0% | 1↑ 0↓ | $0.7B | 1 |
| Next FY | $1.25 | $1.25–$1.25 | 25.0% | +0.0% | 0↑ 1↓ | $0.7B | 1 |
| Current Q | $0.16 | $0.16–$0.16 | -5.9% | +0.0% | 0↑ 1↓ | $0.2B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.160 | — |
| 7d ago | $0.160 | — |
| 30d ago | $0.160 | — |
| 60d ago | $0.220 | -0.060 |
| 90d ago | $0.240 | -0.080 |
Institutional ownership
Which big funds own AVNS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $720.2M total value (29,046,929 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 27 institutions added/increased vs 23 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,468,794 | $185.8M | 25.8% | — |
| STATE STREET CORP | 2,010,691 | $50.0M | 6.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,993,794 | $49.6M | 6.9% | — |
| MILLENNIUM MANAGEMENT LLC | 1,524,553 | $37.9M | 5.3% | DOUBLED +10926.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,181,164 | $29.4M | 4.1% | — |
| JPMORGAN CHASE & CO | 1,099,770 | $27.4M | 3.8% | DOUBLED +337.9% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 946,344 | $23.5M | 3.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 937,205 | $23.3M | 3.2% | — |
| FIL Ltd | 815,000 | $20.3M | 2.8% | NEW |
| GOLDMAN SACHS GROUP INC | 765,416 | $19.0M | 2.6% | ADD +59.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 13,826 | 1,524,553 | +10926.7% | $37.9M |
| JPMORGAN CHASE & CO | DOUBLED | 251,162 | 1,099,770 | +337.9% | $27.4M |
| FIL Ltd | NEW | — | 815,000 | — | $20.3M |
| GOLDMAN SACHS GROUP INC | ADD | 480,886 | 765,416 | +59.2% | $19.0M |
| Pentwater Capital Management LP | NEW | — | 750,000 | — | $18.7M |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 739,829 | — | $18.4M |
| Qube Research & Technologies Ltd | DOUBLED | 129,593 | 554,350 | +327.8% | $13.8M |
| MORGAN STANLEY | TRIM | 827,662 | 472,644 | -42.9% | $11.8M |
| Squarepoint Ops LLC | NEW | — | 418,660 | — | $10.4M |
| Allianz Asset Management GmbH | ADD | 265,572 | 373,397 | +40.6% | $9.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | AWARD | 96,121 | — | — |
| Jul 27, 2026 | Delgado Sigfrido | SVP, Operations | AWARD | 54,886 | — | — |
| Jul 27, 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | D | 96,121 | $25.00 | $2.4M |
| Jul 27, 2026 | Delgado Sigfrido | SVP, Operations | D | 54,886 | $25.00 | $1.4M |
| Jul 27, 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | D | 69,630 | — | — |
| Jul 27, 2026 | Delgado Sigfrido | SVP, Operations | D | 37,520 | — | — |
| Jul 27, 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | D | 21,038 | — | — |
| Jul 27, 2026 | Delgado Sigfrido | SVP, Operations | D | 21,914 | — | — |
| Jul 27, 2026 | Pacitti David | Chief Executive Officer | D | 322,194 | $25.00 | $8.1M |
| Jul 27, 2026 | Pacitti David | Chief Executive Officer | AWARD | 444,730 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AVNS.
Shares short
1,751,047
Settlement Jul 15, 2026
Change vs prior
-1.3%
Semi-monthly cycle
Days to cover
2.4
At avg daily volume
Of shares outstanding
≈3.7%
Estimate — not % of float
All AVNS filing & press-release reports (7)
- 25-NSE reportJul 27, 2026
- 8-K, DEFA14A reportJul 2, 2026
- DEFM14A reportJun 10, 2026
- DEFA14A reportMay 5, 2026
- DEFA14A reportApr 23, 2026
- DEFA14A reportApr 14, 2026
- 8-K reportFeb 26, 2026